PMID- 20843314
OWN - NLM
STAT- MEDLINE
DCOM- 20101228
LR  - 20211020
IS  - 1756-9966 (Electronic)
IS  - 0392-9078 (Print)
IS  - 0392-9078 (Linking)
VI  - 29
IP  - 1
DP  - 2010 Sep 15
TI  - Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks 
      from fine-needle aspirates of non small cell lung carcinomas and lung metastases 
      from colo-rectal cancer.
PG  - 125
LID - 10.1186/1756-9966-29-125 [doi]
AB  - BACKGROUND: Several studies demonstrated that epidermal growth factor receptor 
      (EGFR) gene copy number (GCN) correlates to the response to tyrosine kinase 
      inhibitors in non small cell lung cancer (NSCLC) and to anti-EGFR monoclonal 
      antibodies (MoAbs) in metastatic colorectal cancer (CRC). In the presence of lung 
      nodules, cytology is often the only possible diagnostic approach. Chromogenic in 
      situ hybridization (CISH) is an alternative technique to fluorescence in situ 
      hybridization (FISH), but its feasibility in detecting EGFR GCN in cell blocks 
      from fine-needle aspiration cytology (FNAC) of lung nodules has not yet been 
      established. METHODS: We evaluated the feasibility of CISH on 33 FNAC from 20 
      primary NSCLC (5 squamous carcinomas, 8 large cell carcinomas and 7 
      adenocarcinomas) and 13 lung metastases from CRC. RESULTS: Of the 33 FNAC 
      analyzed by CISH, 27 (82%) presented a balanced increase in EGFR gene and 
      chromosome 7 number: 10 cases (30%) showed a low polysomy, 15 (45%) a high 
      polysomy and 2 (6%) NSCLC were amplified. No significant differences between 
      NSCLC and CRC lung metastases were found in relation to disomic or polysomic 
      status. In addition, no correlation between EGFR GCN and EGFR immunohistochemical 
      overexpression was found. Furthermore, we compared CISH results with those 
      obtained by FISH on the same samples and we found 97% overall agreement between 
      the two assays (k = 0.78, p < 0.0001). Two cases were amplified with both assays, 
      whereas 1 case of NSCLC was amplified by FISH only. CISH sensitivity was 67%, the 
      specificity and positive predictive value (PPV) was 100%, and the negative 
      predictive value (NPV) was 97%. CONCLUSIONS: Our study shows that CISH is a valid 
      method to detect EGFR GCN in cell blocks from FNAC of primary NSCLC or metastatic 
      CRC to the lung.
FAU - Simone, Giovanni
AU  - Simone G
AD  - Pathology Department, Giovanni Paolo II National Cancer Institute, via Hahnemann 
      10, Bari, Italy. g.simone@oncologico.bari.it
FAU - Mangia, Anita
AU  - Mangia A
FAU - Malfettone, Andrea
AU  - Malfettone A
FAU - Rubini, Vincenza
AU  - Rubini V
FAU - Siciliano, Michele
AU  - Siciliano M
FAU - Di Benedetto, Anna
AU  - Di Benedetto A
FAU - Terrenato, Irene
AU  - Terrenato I
FAU - Novelli, Flavia
AU  - Novelli F
FAU - Mottolese, Marcella
AU  - Mottolese M
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100915
PL  - England
TA  - J Exp Clin Cancer Res
JT  - Journal of experimental & clinical cancer research : CR
JID - 8308647
RN  - 0 (Chromogenic Compounds)
RN  - 6SO6U10H04 (Biotin)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - NQ1SX9LNAU (Digoxigenin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aneuploidy
MH  - *Biopsy, Fine-Needle
MH  - Biotin
MH  - Carcinoma, Non-Small-Cell Lung/chemistry/*genetics/pathology
MH  - *Chromogenic Compounds
MH  - Chromosomes, Human, Pair 7
MH  - Colorectal Neoplasms/chemistry/*genetics/pathology
MH  - Digoxigenin
MH  - ErbB Receptors/analysis/*genetics
MH  - Feasibility Studies
MH  - Female
MH  - *Gene Dosage
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization/*methods
MH  - In Situ Hybridization, Fluorescence
MH  - Italy
MH  - Lung Neoplasms/chemistry/*genetics/pathology/secondary
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Reproducibility of Results
MH  - Retrospective Studies
PMC - PMC2954880
EDAT- 2010/09/17 06:00
MHDA- 2010/12/29 06:00
PMCR- 2010/09/15
CRDT- 2010/09/17 06:00
PHST- 2010/05/26 00:00 [received]
PHST- 2010/09/15 00:00 [accepted]
PHST- 2010/09/17 06:00 [entrez]
PHST- 2010/09/17 06:00 [pubmed]
PHST- 2010/12/29 06:00 [medline]
PHST- 2010/09/15 00:00 [pmc-release]
AID - 1756-9966-29-125 [pii]
AID - 10.1186/1756-9966-29-125 [doi]
PST - epublish
SO  - J Exp Clin Cancer Res. 2010 Sep 15;29(1):125. doi: 10.1186/1756-9966-29-125.